BAVARIAN NORDIC

Strategies for improving Ebola virus disease post-exposure prophylaxis, origin of SARS-CoV-2 linked to Wuhan market, 'scoop and run' best for nerve agent mass casualty events, T cell memory from seasonal flu may offer pre-existing immunity to H5N1.

MaxCyte partners with Kamau Therapeutics, Arvato Systems with Advanco, Revance Therapeutics' acquisition impacted by Crown Laboratories, Lifebit and CanPath strategic partnership, Kajeet and Avery Telehealth partnership. FDA approves Apple's sleep apnea detection, Roche's Ocrevus injectable, Novartis Kisqali, Lilly's EBGLYSS, issues alert on Astellas' Veozah, clears Eversense CGM system. Nura Bio raises $68 million, Arzeda $38 million. Cigna's Express Scripts sues FTC, Burson launches Decipher Health, short interest in healthcare stocks rises, Hill Holliday's Quest, Ascendis Pharma's positive Phase 3 results, WHO approves Bavarian Nordic's mpox vaccine, J&J's talc verdict overturned, Prime Therapeutics' new vision, Blue Matter acquires Sam Brown Inc.

The EU approves Bavarian Nordic's mpox vaccine for adolescents aged 12-17, based on clinical study data showing comparable immune responses and safety profiles to adults. This follows the approval of Mvabea® for younger populations in 2020. The vaccine, effective against mpox, aims to improve access for vulnerable populations, particularly in Africa, where the outbreak is severe.

EMA approves MVA-BN for mpox and smallpox in adolescents 12-17, second approval for MVA-BN in younger population. Clinical study data supported approval, showing non-inferior immune responses and similar safety profile. Bavarian Nordic plans further trials for younger children.

Bavarian Nordic could produce 50 million more doses with new processes and partners.

Bavarian Nordic’s mpox vaccine added to WHO’s prequalified list.

WHO prequalified MVA-BN as the first mpox vaccine, aiming to boost access and contain outbreaks. Bavarian Nordic plans to supply 10 million doses by 2025. The vaccine is 99.2% effective after two doses, according to CDC data.

WHO approves MVA-BN mpox vaccine, facilitating access for millions at risk in Africa. The vaccine, already approved in Europe and the U.S., is recommended for adults in two doses, with an 82% effectiveness. In limited supply situations, single doses are 76% effective. WHO aims for urgent scale-up in procurement and distribution to prevent infections and save lives.

WHO approved MVA-BN mpox vaccine for first time, aiming to facilitate timely access for millions at risk in Africa. The vaccine, already approved in Europe and the US, can be administered in two doses with 82% effectiveness. WHO's prequalification aims to accelerate procurement and regulatory approval worldwide.

WHO approves MVA-BN as first pre-qualified mpox vaccine, with single-dose effectiveness at 76% and two-dose at 82%. WHO chief emphasizes urgent vaccine procurement and roll-out for equitable access.